Mucormycosis is an opportunistic, invasive fungal disease caused by mucormycetes. It is most common in highly immunocompromised hosts in developing countries. Absorption or inhalation of sporangiospores or inoculation of conidia by puncture trauma or wounds are the initial steps in the pathogenesis of mucormycosis. There are few high-quality reports on its implications in dental practice and Oral mucormycosis is usually caused by inhalation of spores or direct contamination of open oral wound. The most common form of this disease in maxillofacial region is rhino cerebral mucormycosis, with widespread involvement of oral cavity, maxilla, palate, nose, paranasal sinuses, orbits and central nervous system. Failure of prompt medical and surgical intervention may lead to cerebral spread, cavernous sinus thrombosis, septicemia and multiple organ failure lending to high morbidity and mortality .Amphotericin B is the drug of choice in mucormycosis. Supportive therapy includes; fluid balance, nutritional supplements and correction of underlying immune deficiency. Surgical management included combination of one or more procedures like tissue debridement, maxillectomy, sinus exploration and curettage. Newer drugs, adjuvant therapy like iron chelators and hyperbaric oxygen therapy has also been reported for treatment of mucormycosis.